Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma-Reference-Cited by-同舟云学术

Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma

Published:2018-12-13 Issue: Volume: Page:
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Binder Moritz¹^ORCID,Rajkumar S. Vincent¹^ORCID,Lacy Martha Q.¹,Gertz Morie A.¹^ORCID,Buadi Francis K.¹,Dispenzieri Angela¹,Hwa Yi L.¹,Fonder Amie¹,Hobbs Miriam¹,Hayman Suzanne R.¹,Zeldenrust Steven R.¹,Lust John A.¹,Russell Stephen J.¹,Leung Nelson¹^ORCID,Kapoor Prashant¹,Go Ronald S.¹^ORCID,Gonsalves Wilson I.¹^ORCID,Kourelis Taxiarchis¹^ORCID,Warsame Rahma¹^ORCID,Kyle Robert A.¹,Kumar Shaji K.¹

Affiliation:

1. Division of HematologyMayo Clinic Rochester Minnesota

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25365

Reference29 articles.

1. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy;Khalil DN;Nat Rev Clin Oncol.,2016

2. T cells genetically modified to express an anti‐B‐cell maturation antigen chimeric antigen receptor cause remissions of poor‐prognosis relapsed multiple myeloma;Brudno JN;J Clin Oncol.,2018

3. Final analysis of survival outcomes in the phase 3 FIRST trial of up‐front treatment for multiple myeloma;Facon T;Blood.,2018